PrecisionBio Reports 7.1 Billion KRW in Q1 Sales... Operating Profit Turns Positive View original image

[Asia Economy Reporter Lee Gwan-joo] Precision Bio, a company specializing in in vitro diagnostics, announced on the 17th that its sales in the first quarter of this year reached 7.1 billion KRW, a 300% increase compared to the same period last year. Operating profit turned positive at 40 million KRW.


Thanks to the continued strong sales of animal clinical chemistry diagnostic products launched last year and increased sales of COVID-19 antigen diagnostic cartridges by its subsidiary Nanodetec, which obtained Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), the company achieved five consecutive quarters of sales growth.


By product, sales of immunodiagnostic products amounted to 4.7 billion KRW, and clinical chemistry products recorded 2.4 billion KRW. Domestic sales accounted for 2.4 billion KRW (34%), while the U.S. and Europe each accounted for 1.7 billion KRW (24%).


Since last month, Precision Bio has launched immunodiagnostic products for testing COVID-19 and influenza in Japan, and is promoting entry into the North American and Latin American markets to expand sales of animal clinical chemistry products.



A Precision Bio official explained, "In the first quarter, sales related to COVID-19 testing increased due to a surge in domestic and international demand, but a decline in diagnostic product sales is expected in the second quarter. However, as hospital visits in Europe and other regions return to pre-COVID levels, demand for our main products, such as cardiovascular immunodiagnostic products and human clinical chemistry products, is showing signs of recovery."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing